pharmaceutical investing U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
pharmaceutical investing Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
pharmaceutical investing PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
pharmaceutical investing Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
pharmaceutical investing Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
pharmaceutical investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
